Anderson Scott R, Ayoub Malek, Coats Sarah, McHenry Scott, Tan Tingyi, Deepak Parakkal
Division of Gastroenterology, Washington University School of Medicine, St. Louis, Missouri, USA.
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA .
Am J Gastroenterol. 2025 May 1;120(5):1152-1155. doi: 10.14309/ajg.0000000000003208. Epub 2024 Nov 14.
The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood.
Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response.
Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year ( P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores.
GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.
胰高血糖素样肽受体激动剂（GLP1-RA）在炎症性肠病（IBD）患者中的安全性和有效性尚不清楚。
回顾性确定接受GLP1-RA治疗的IBD患者的不良事件、体重变化以及临床、内镜和生物标志物反应结果。
在总共120例IBD患者中，胃肠道副作用最为常见（11.5%）。司美格鲁肽显示出最显著的体重减轻。一年后C反应蛋白水平下降（P = 0.005）。在IBD相关住院或内镜评分方面未观察到差异。
GLP1-RA治疗在IBD患者中似乎安全有效，且伴有C反应蛋白降低。
